ArticleClinical neuropsychiatry2019
Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs.
Article in Clinical neuropsychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs.European journal of psychotraumatology · 2024Pooled it
- Computational modelling and neural correlates of reinforcement learning following three-week escitalopram: a double-blind, placebo-controlled semi-randomised study.Translational psychiatry · 2025Trial
- Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.BMC psychiatry · 2024Trial
- Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.British journal of pharmacology · 2026Review
- The Therapeutic Potential of Mesenchymal Stem Cells in Post-Stroke Depression.International journal of molecular sciences · 2026Review
- AdipoRon as a Novel Therapeutic Agent for Depression: A Comprehensive Review of Preclinical Evidence.Biomedicines · 2025Review
- Effects of arabinoxylan on BDNF/TrkB/p-CREB signaling pathway in the prefrontal cortex and intestinal microbiome in post-stroke depressed rats.BMC neuroscience · 2025Article
- Therapeutic Potential of Cinnamon Oil: Chemical Composition, Pharmacological Actions, and Applications.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.Psychopharmacology · 2024Article
- Article
- Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Negative emotionality downregulation affects moral choice but not moral judgement of harm: a pharmacological study.Scientific reports · 2024Article
- Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study.Neuropsychiatric disease and treatment · 2024Article
- Mechanisms associated with post-stroke depression and pharmacologic therapy.Frontiers in neurology · 2023Review
- Anxiolytic-like Effect of Inhaled Cinnamon Essential Oil and Its Main Component Cinnamaldehyde in Animal Models.Molecules (Basel, Switzerland) · 2022Article
- Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life.Annals of general psychiatry · 2022Article
- Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.BMJ medicine · 2022Article
- Neuroenhancement: State of the Art and Future Perspectives.Clinical neuropsychiatry · 2021Article
- Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSelective serotonin (5-HT) reuptake inhibitors (SSRIs) are amongst the most prescribed drugs worldwide not only for psychiatric conditions, but also for medical purposes. Converging data gathered throughout the decades following their development would indicate that SSRIs have a broader side effect profile than previously assumed. Therefore, the aim of the present paper was to to review available literature highlighting less common side effects emerging with their long-term use.
methodThis systematic review, carried out according to PRISMA guidelines, was performed through searching electronic databases of PubMed, Google Scholar, Cochrane Library, Embase, MEDLINE, PsycINFO and Scopus. The keyword used was "SSRIs" combined with the following: "Side effects", or "Emotional blunting or flattening", or "Cognition", or "Neuroimaging", or "Bone", "or "Platelet aggregation", or "Bleeding".
resultsThe most common side effects, besides the classical ones described in the literature are represented by decreased emotional response to both adversive and pleasurable events, some cognitive impairments, bone fractures and prolonged overall bleeding time.
conclusionsAfter analyzing critically the available findings, it should be noted that only the so-called "emotional blunting" is supported by converging data, while results on cognitive impairment are extremely controversial, given some evidence showing that SSRIs may improve cognition. Similarly, no agreement exists on the detrimental effects of SSRIs on bone metabolism and coagulation.Large, prospective and long-term studies are needed to clarify the possible impact of SSRIs on emotions, cognitive functions, bone fractures and coagulation, as well to detect other possible still neglected side effects.
Indexed as
Identifiers
34908941PMC8650205W4206854864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.